Εμφάνιση απλής εγγραφής

dc.creatorThomas K., Lazarini A., Kaltsonoudis E., Voulgari P.V., Drosos A.A., Repa A., Sali A.M.I., Sidiropoulos P., Tsatsani P., Gazi S., Evangelia A., Boki K.A., Katsimbri P., Boumpas D., Fragkiadaki K., Tektonidou M.G., Sfikakis P.P., Karagianni K., Sakkas L.I., Grika E.P., Vlachoyiannopoulos P.G., Evangelatos G., Iliopoulos A., Dimitroulas T., Garyfallos A., Melissaropoulos K., Georgiou P., Areti M., Georganas C., Vounotrypidis P., Georgiopoulos G., Kitas G.D., Vassilopoulos D.en
dc.date.accessioned2023-01-31T10:08:29Z
dc.date.available2023-01-31T10:08:29Z
dc.date.issued2021
dc.identifier10.1093/rheumatology/keaa557
dc.identifier.issn14620324
dc.identifier.urihttp://hdl.handle.net/11615/79707
dc.description.abstractObjectives: Predicting serious infections (SI) in patients with rheumatoid arthritis (RA) is crucial for the implementation of appropriate preventive measures. Here we aimed to identify risk factors for SI and to validate the RA Observation of Biologic Therapy (RABBIT) risk score in real-life settings. Methods: A multi-centre, prospective, RA cohort study in Greece. Demographics, disease characteristics, treatments and comorbidities were documented at first evaluation and one year later. The incidence of SI was recorded and compared with the expected SI rate using the RABBIT risk score. Results: A total of 1557 RA patients were included. During follow-up, 38 SI were recorded [incidence rate ratio (IRR): 2.3/100 patient-years]. Patients who developed SI had longer disease duration, higher HAQ at first evaluation and were more likely to have a history of previous SI, chronic lung disease, cardiovascular disease and chronic kidney disease. By multivariate analysis, longer disease duration (IRR: 1.05; 95% CI: 1.005, 1.1), history of previous SI (IRR: 4.15; 95% CI: 1.7, 10.1), diabetes (IRR: 2.55; 95% CI: 1.06, 6.14), chronic lung disease (IRR: 3.14; 95% CI: 1.35, 7.27) and daily prednisolone dose ≥10 mg (IRR: 4.77; 95% CI: 1.47, 15.5) were independent risk factors for SI. Using the RABBIT risk score in 1359 patients, the expected SI incidence rate was 1.71/100 patient-years, not different from the observed (1.91/100 patient-years; P = 0.97). Conclusion: In this large real-life, prospective study of RA patients, the incidence of SI was 2.3/100 patient-years. Longer disease duration, history of previous SI, comorbidities and high glucocorticoid dose were independently associated with SI. The RABBIT score accurately predicted SI in our cohort. © 2020 The Author(s). Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved.en
dc.language.isoenen
dc.sourceRheumatology (United Kingdom)en
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85107084007&doi=10.1093%2frheumatology%2fkeaa557&partnerID=40&md5=71cb96bb53b22957acb2e87e307fbdc3
dc.subjectbiological producten
dc.subjectcorticosteroiden
dc.subjectdisease modifying antirheumatic drugen
dc.subjectglucocorticoiden
dc.subjecthydroxychloroquineen
dc.subjectleflunomideen
dc.subjectmethotrexateen
dc.subjectprednisoloneen
dc.subjectantirheumatic agenten
dc.subjectadulten
dc.subjectArticleen
dc.subjectcardiovascular diseaseen
dc.subjectcentral nervous system infectionen
dc.subjectchronic lung diseaseen
dc.subjectclinical featureen
dc.subjectcohort analysisen
dc.subjectcombination drug therapyen
dc.subjectcomorbidityen
dc.subjectcomparative studyen
dc.subjectcontrolled clinical trialen
dc.subjectcontrolled studyen
dc.subjectDAS28en
dc.subjectdemographyen
dc.subjectdiabetes mellitusen
dc.subjectdisease durationen
dc.subjectdisease risk assessmenten
dc.subjectestimated glomerular filtration rateen
dc.subjectfemaleen
dc.subjectgastrointestinal infectionen
dc.subjectherpes zosteren
dc.subjectherpetic stomatitisen
dc.subjecthospitalizationen
dc.subjecthumanen
dc.subjectincidenceen
dc.subjectinfectionen
dc.subjectinfection risken
dc.subjectlung tuberculosisen
dc.subjectmajor clinical studyen
dc.subjectmaleen
dc.subjectmonotherapyen
dc.subjectmulticenter studyen
dc.subjectmusculoskeletal disease assessmenten
dc.subjectopportunistic infectionen
dc.subjectparasitosisen
dc.subjectprospective studyen
dc.subjectpyelonephritisen
dc.subjectrespiratory tract infectionen
dc.subjectrheumatoid arthritisen
dc.subjectrheumatoid arthritis observation of biologic therapy risk scoreen
dc.subjectskin infectionen
dc.subjectskin structureen
dc.subjectspondylitisen
dc.subjecttuberculosisen
dc.subjectvalidation studyen
dc.subjectvirus infectionen
dc.subjectageden
dc.subjectmiddle ageden
dc.subjectopportunistic infectionen
dc.subjectrheumatoid arthritisen
dc.subjectrisk factoren
dc.subjectAgeden
dc.subjectAntirheumatic Agentsen
dc.subjectArthritis, Rheumatoiden
dc.subjectComorbidityen
dc.subjectFemaleen
dc.subjectGlucocorticoidsen
dc.subjectHumansen
dc.subjectIncidenceen
dc.subjectInfectionsen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectOpportunistic Infectionsen
dc.subjectRisk Factorsen
dc.subjectOxford University Pressen
dc.titleIncidence, risk factors and validation of the RABBIT score for serious infections in a cohort of 1557 patients with rheumatoid arthritisen
dc.typejournalArticleen


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής